Shares of Amgen (NASDAQ: AMGN) and Cytokinetics (NASDAQ: CYTK) have closed lower after the companies, along with French firm Servier, reported topline results of the experimental heart drug omecamtiv mecarbil.
The study, named GALACTIC-HF, was closely watched. While it met its primary endpoint of reducing the time until patients passed away or needed treatment compared to placebo patients, there was no reduction in the secondary endpoint of cardiovascular death.
GALACTIC-HF was one of the most extensive Phase 3 studies in heart failure ever conducted and included over 8,000 patients from 35 countries.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The feeling amongst analysts is that the data was underwhelming and disappointing, which resulted in both Amgen and Cytokinetics stock plummeting on Thursday.
Both companies were unenthusiastic in their statements with Executive Vice President of Research and Development at Amgen, David M. Reese MD saying that “the outcomes observed in GALACTIC-HF further the understanding of treating heart failure.”
Fady I. Malik MD, PhD, executive vice president of research and development at Cytokinetic said: “GALACTIC-HF provides insights into effects associated with targeting cardiac muscle contractility with omecamtiv mecarbil to treat heart failure patients with reduced ejection fraction.”
The trial result saw Cytokinetics stock plummet 42.14% to $16 on Thursday, making it the biggest loser of the day in US stocks, while Amgen stock closed 6.82% lower at $240.09 per share.
PEOPLE WHO READ THIS ALSO VIEWED:
